BMJ to bar papers when patient-level data kept private

Share this article:
Fiona Godlee
Fiona Godlee

Starting next year, the BMJ will not publish academic papers on drugs or devices unless the relevant anonymized patient-level data are made available for third-party study.

The journal, which announced the policy October 30, will require this commitment for all clinical trials of drugs and devices starting in January 2013.

In an editorial, Fiona Godlee, BMJ's editor in chief, said that the fact that such data are kept private has made it harder to assess drug safety and efficacy.

The journal's show of power is the latest attempt to get drugmakers to take the wraps off data. Earlier this year, Cochrane Collaboration researchers accused Roche of author bias in the trial program for Tamiflu.

When patient-level clinical research data are made available for independent scrutiny, academics and companies say, better treatment decisions about drugs can be made.

While this data is often withheld by industry, some have pledged to open up. Medtronic has pledged to release all relevant clinical research data into the public domain in a partnership with Yale University, and  GlaxoSmithKline in October said that it would make such data available from its trials.

In a statement, GSK's Patrick Vallance, president, pharmaceuticals R&D, noted, “Moves like this should help medical research by allowing scientists to study the detailed results of clinical trials and increase understanding of current and new medicines.”
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric